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OBJECTIVES: To evaluate cost-effectiveness of entecavir (ETV)
vs. lamivudine (LVD) in treating CHB in Poland. METHODS:
A decision tree model was developed to project over a period of
10 years the number of cirrhosis (compensated and decompen-
sated) and hepatocellular carcinoma events based on serum HB
viral-DNA levels. Two hypothetical cohorts of CHB patients
treated for 2 years were studied: 1) nucleoside-naïve patients
treated with ETV (0.5 mg/day) vs. LVD (100 mg/day) and ade-
fovir (ADV) as salvage therapy in case of LVD resistance; and 2)
LVD-refractory patients treated with ETV (1 mg/day) vs. ADV
(10 mg/day). Effectiveness was measured as quality-adjusted life
year (QALY). Efﬁcacy data, the risk predicting models, utility
scores and medical costs for CHB disease stages were obtained
from published literatures. Life expectancy was estimated using
Polish life tables and published literature. A Polish health care
payer perspective was considered and a 5% discount rate was
used for both costs and outcomes. Sensitivity analyses to treat-
ment patterns, costs and utilities were performed. RESULTS:
Resistance to treatment with LVD was associated with lower efﬁ-
cacy and increased costs. In nucleoside-naïve HBeAg+ patients,
ETV compared with LVD therapy with ADV salvage saved
369,676/373,701 PLN and gained 28/30 QALYs for 100
men/women, respectively. For nucleoside-naïve HBeAg-patients,
savings were 185,066/187,564 PLN and QALYs gained 13/15
for 100 men/women, respectively. In LVD-refractory patients,
ETV therapy was associated with savings of 424,383/429,007
PLN and QALYs gained of 26/29 for 100 men/women, respec-
tively. Results were robust to sensitivity analyses. CONCLU-
SION: This cost-effectiveness analysis suggests that in the Polish
health care system, ETV dominates LVD to treat CHB in nucle-
oside-naïve and LVD-refractory patients. Due to differences in
life expectancy between men and women, cost-effectiveness
results are more favorable for women with CHB.
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OBJECTIVES: Linezolid, an oxazolidinone antibiotic, has been
shown to be effective in the treatment of complicated skin and
soft-tissue infections (cSSTI) and nosocomial pneumonia (NP)
including ventilator-associated pneumonia (VAP) caused by
methicillin-resistant Staphylococcus aureus (MRSA) in hospital-
ized patients. However, hospital use of linezolid has been limited
by high acquisition cost compared with other antibiotics. The
objective was to compare the consistency of cost-effectiveness
ﬁndings of linezolid across different health care systems.
METHODS: Separate studies were conducted in Brazil, Italy,
Germany, Spain, and the US to estimate the cost-effectiveness of
linezolid for the treatment of gram-positive infections. In all
studies (except US), a decision-analytic model was used to
predict the cost-effectiveness of linezolid vs vancomycin or
teicoplanin in each country. For the US, resource use data were
obtained from a multicenter trial. For all other countries, clini-
cal efﬁcacy data were obtained from multinational clinical trials,
cost data were based on published literature and local govern-
ment sources, and a Delphi panel comprising local experts pro-
vided input into health care resource utilization data. RESULTS:
In all health care systems, linezolid was cost-effective due to its
superior clinical cure and survival (in NP). In cSSTI, total treat-
ment costs were less expensive by $153 (Germany), $787 (Spain)
and $873 (US) mainly due to reduction in length of stay. In Italy,
treatment costs were similar (linezolid was $77 more). In VAP,
cost per life year saved was $380 in Spain and cost saving in
Brazil. Similarly, cost for life year gained for NP was $460.
CONCLUSION: All studies showed that despite higher acquisi-
tion cost, linezolid is either cost-saving or cost-effective for hos-
pitalized patients with gram-positive infections across multiple
health care systems due to its higher clinical efﬁcacy in terms of
cure and survival rates.
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OBJECTIVES: Darunavir (TMC114; DRV) is a novel protease
inhibitor (PI) with demonstrated superior efﬁcacy to currently
available PIs for the treatment of HIV infection in treatment-
experienced adults who have failed prior antiretroviral therapy.
We evaluated the cost-effectiveness (CE), from a Canadian
provincial Ministry of Health perspective, of ritonavir-boosted
DRV (DRV/r) plus an optimized background regimen (OBR)
compared to currently available PIs plus OBR (control).
METHODS: A Markov model with 3-month cycles was devel-
oped to follow patients through 6 possible health states deﬁned
by CD4 cell count ranges. Costs (in 2006 Canadian dollars) were
assumed to accrue based on estimates of health care services used
during each health state. Each health state also had an associ-
ated utility value. Cost, utility, and mortality data were estimated
from published Canadian sources. Transition probabilities were
calculated from clinical trials. Both costs and outcomes were dis-
counted at 5%/year. Two analyses were conducted: 1) incre-
mental cost/additional person with viral load <50 copies/mL at
48 weeks; 2) incremental lifetime cost/quality-adjusted life-year
(QALY) gained. Extensive sensitivity and variability (assessing
impact of practice patterns, population and model characteris-
tics) analyses were performed. RESULTS: DRV/r is associated
with a 36% absolute increase in probability of achieving viral
load <50 copies/mL at 48 weeks and a gain of 1.27 QALYs over
a lifetime. The incremental cost/additional person with viral load
<50 copies/mL was $9897; the incremental cost/QALY gained
was $30,907. Sensitivity and variability analyses showed results
were robust. For most of the credible uncertainty ranges, the CE
ratio remained less than $50,000/QALY gained. Variability
analyses showed CE ratios ranged $23,283–$34,667 depending
most heavily on the assumed amount of tipranavir use in the
model control arm and enfuvirtide use in the OBR. CONCLU-
SION: When compared to current standard of care, DRV/r plus
OBR is cost-effective in treatment-experienced adults who have
failed prior antiretroviral therapy.
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BACKGROUND: The cost-effectiveness of routine inﬂuenza vac-
cination in people over 65 is accepted. This study compares the
incremental cost-effectiveness of the MF59 adjuvanted vaccine
Fluad®* to non-adjuvanted vaccines in France in situations where
the circulating strain matches the strain prepared in the vaccine,
and also where there is antigenic drift—where the circulating
strain differs slightly from the one included in the vaccine.
METHODS: A decision analysis model was developed using evi-
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dence from clinical studies concerning the relative effectiveness
of Fluad® and non-adjuvanted vaccines in the over 65 popula-
tion. Evidence concerning the impact of Fluad® on hospitalisa-
tion was taken from an observational study, other resource use
parameters and costs from the literature. The analysis was per-
formed from the payer perspective (direct medical costs).
RESULTS: Based on the increased protective efﬁcacy of Fluad®
compared to non-adjuvanted vaccines, we estimated a reduction
in cases of between 11.8% and 23.8% depending on the inﬂuenza
strain circulating in the community. Using these estimates, for an
attack rate of Inﬂuenza-like Illness of 5% and a discount rate of
3%, the incremental cost per life year gained (CLYG) ranged from
€3103 to €23,894. In situations where there is antigenic drift
(which occurs every 2–5 years), all vaccines are less effective.
However, the efﬁcacy of Fluad® falls by only 2%, whereas that
of non-adjuvanted vaccines falls by 22%. With antigenic drift,
the cost-effectiveness of Fluad® compared to non-adjuvanted vac-
cines is enhanced due to the better protective effect, and depend-
ing on the circulating strain, ranged from being cost saving to an
incremental CLYG of €5709. CONCLUSION: Compared to non-
adjuvanted vaccines, Fluad® is cost-effective. Since the estimated
cost per life year gained is within acceptable thresholds, Fluad®
should be used as the vaccine of choice in older people. * Fluad®
is registered under the trade name Gripguard® in France.
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OBJECTIVES: To evaluate the cost-effectiveness of three differ-
ent immunization strategies (1st: one time routine vaccination of
all adolescents aged 11 years [yr], 2nd: college freshmen aged 18
yr, and 3rd: college freshmen living in dormitories aged 18 yr)
with meningococcal polysaccharide (serogroups A, C, Y and W-
135) vaccine [MCV4] compared to no vaccination from a soci-
etal perspective. METHODS: A decision analysis model using
backward induction method was employed with parameter
values from published literature and HCUPnet (Health care Cost
and Utilization Project). All subjects were followed until they
reached 29 yr-old. Direct costs (vaccine, administration, hospi-
talization, outbreak control, and lifetime care) and indirect costs
(patient and health care workers time cost) were measured in
2005 US$. Effectiveness was measured as quality adjusted life
years [QALYs]. All costs and QALYs were discounted at 3% and
cost-effectiveness was measured as incremental cost per QALYs
gained [ICER]. Uncertainty was evaluated using multiple one-
way sensitivity analyses. RESULTS: All strategies yielded favor-
able ICERs ($16,746, $29,447, and $19,203 for 1st, 2nd, and
3rd strategy, respectively). The results were more favorable when
herd immunity was considered ($9916, $18,163, and $11,402
for 1st, 2nd, and 3rd strategy, respectively). All strategies were
highly sensitive to the duration of vaccine efﬁcacy and the dis-
count rate. A 50% decrease in these parameter values led to more
than a 100% change in ICERs. The herd immunity effect of
25%, 50%, and 75% lead approximately to 25%, 40%, and
50% change in ICERs. The model was sensitive to the disease
incidence rate, the risk for sequelae, and the vaccine cost, but
not to direct costs for treatment and the vaccine efﬁcacy. CON-
CLUSION: Three immunization strategies were cost-effective
compared to no vaccination using a societal threshold cut-off of
$50,000 per QALY. This analysis shows the opposite result to
previous U.S. ﬁndings. Further research is needed to explain
these discrepancies.
PIN17
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OBJECTIVES: To examine the cost-effectiveness of PCV and to
determine if there is any long-term cost offset if it became a
routine vaccination for infants. METHODS: Two hypothetical
cohorts of 1000 infants (one vaccinated and one unvaccinated)
were followed over lifetime. A decision analytical model was
used to analyze the cost and cost-effectiveness of the vaccine
from a government’s perspective. The probabilities of events of
invasive pneumococcal diseases (IPD) and otitis media (OM)
were derived from published local or overseas data. Vaccine efﬁ-
cacy (mid-range) from overseas trials was used. Cost avoidance
arising from herd immunity was calculated based on overseas
published data. Cost of management of complications arising
from pneumococcal infections was estimated from a group of
hospitalized or outpatient cases from 2 large regional public hos-
pitals in Hong Kong. The costs associated with non-hospitalized
disease states were captured through interviews with a group of
identiﬁed GPs selected from different regions in Hong Kong. Vac-
cination programme costs included vaccine acquisition cost and
cost of administration. Productivity loss was assessed in terms of
extra care from family members, reduced earning ability and
early retirement due to disability, absenteeism, and premature
death. RESULTS: After a routine four-dose vaccination of infants
in their ﬁrst year of life, the PCV was estimated to have averted
566 cases of IPD and 2562 cases of OM. Using a discount rate
of 5% for all projections, the direct and indirect costs per life
year gained (CLYG) is HKD94,300 (USD12,090, 1USD =
7.8HKD) and HKD63,000 (USD8077) if no herd effect was
included. With herd immunity included, the direct and indirect
CLYG is reduced to HKD58,600 (USD7513) and HKD38,000
(USD4890) respectively. CONCLUSION: PCV appears to be
cost-saving by averting IPD and related complications and also
cost-effective due to herd immunity.
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OBJECTIVES: Evaluate the pharmacoeconomic impact of seven-
valent pneumococcal conjugate vaccine (Prevnar®) in a Cana-
dian population, accounting for herd immunity effects in
unvaccinated adults. METHODS: A cost-effectiveness analysis
was performed to compare costs and outcomes attributable to
invasive pneumococcal disease (IPD) and non-IPD in the periods
before (1998–2001) and after (2003–2005) the introduction of
Prevnar®. The main outcomes analyzed included total cases,
quality adjusted life years (QALY), and total cost for health
states bacteremia, meningitis, pneumonia, otitis media, myringo-
tomy, and death. Outcomes were based on real-world epidemi-
ology data from Calgary. Resource utilization was derived from
a Canadian Institute for Health Information database and, as
necessary, from the literature and expert opinion. All costs (in
2006 Canadian dollars) and outcomes were discounted by 3%.
